Probiotic efficacy for fatty liver disease

Comparative Effect of Two treatment regimens (Probiotics vs Placebo) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) reporting at SRMSIMS Bareilly, UP

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/051179

Enrollment

450

Registered

2023-03-29

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Probiotics: â?? These will be given as capsular preparations. Each pill will contain 35 billion live organisms, including 12.5 Billion Lactobacillus acidophilus NCFM, 12.5 Billion bifid

Eligibility

Inclusion criteria

Inclusion criteria: Known NAFLD cases in General medicine OPD & IPD of SRMS IMS hospital Bareilly

Exclusion criteria

Exclusion criteria: History of any severe coomplications

Design outcomes

Primary

Measure	Time frame
ALT AST PT INR PLATELET COUNT S ALBUMIN GGT Total Cholesterol Triglyceride Low-Density Lipoprotein Cholesterol High-Density Lipoprotein Cholesterol fasting Serum Glucose inflammatory markers USG FIBROSCAN Metabolic factor Fasting Glucose OGTT SERUM Lipid Profile Timepoint: At baseline, 4 weeks and 8 weeks	—

Secondary

Measure	Time frame
Quality of life and participant satisfaction. Weight, BMI, Adiposity distribution (by measures including waist circumference, waist-to-hip ratio (WHR))Timepoint: 0 4 8 16 32 weeks	—

Countries

India

Contacts

Public ContactDr MP Rawal

Shri Ram Murti Smarak Institute Of Medical Sciences, Bareilly

mahendrapratap.rawal@srmsims.ac.in9760847373

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026